WILEX AG secures further financing with shareholder loans
Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)
| PDF Download
Munich, 17 December 2010. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced that it has signed a subordinated loan agreement for a total amount of up to EUR 10 million, payable in two instalments, with its two main shareholders dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany (dievini) and UCB Pharma S.A., Brussels, Belgium (UCB). dievini grants an amount of EUR 7.5 million and UCB EUR 2.5 million. Both lenders receive interest of 6% p.a.
The loan is without an expiry date and is unsecured. The lenders are entitled to terminate their respective loan agreement upon certain conditions. In this event, the loan becomes due for repayment within one month. Instead of requesting repayment of the loan, the lenders are entitled to repayment by way of a contribution in kind within a capital increase with shareholders subscription rights. Alternatively repayment can be made in return for shares by way of a convertible bond programme yet to be agreed upon. Prerequisite for these repayment options are both the resolution and execution of a capital increase with shareholders subscription rights or of a convertible bond programme as well as an auditor’s certificate of impairment of the respective lender’s claim for repayment of the loan.
Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.